Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 5/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.35 |
| ▸ | GMNN | O75496 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27617039 | 0.89 | MGAM (0.38) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL10697367 | 0.84 | GAA (0.43) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL8911100 | 0.83 | GAA (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL10134701 | 0.83 | GABRP (0.39) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL6156348 | 0.83 | CYP1A2 (0.43) | TSHRCYP1A2LMNAMAPK1GMNN | |
| SCHEMBL7736216 | 0.82 | MGAM (0.44) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL5175797 | 0.81 | LMNA (0.51) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL6036839 | 0.81 | LMNA (0.51) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL28274072 | 0.81 | LMNA (0.39) | TSHRCYP1A2LMNAMAPK1GMNN | |
| SCHEMBL1268514 | 0.80 | GAA (0.43) | MGAMGAASIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111518035-A | Rosuvastatin tert-butylamine salt and preparation method thereof | 安徽鼎旺医药有限公司 | 2020-08-11 | — | — | CN | claimed |
| US-8874019-B2 | Image forming method | KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) | 2014-10-28 | — | — | US | claimed |
| US-20130202336-A1 | IMAGE FORMING METHOD | KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) | 2013-08-08 | — | — | US | claimed |
| CN-106676141-B | Enzymatic preparation method of chiral intermediate (S) -3-hydroxy glutaric acid monoester | 浙江京新药业股份有限公司 | 2020-12-08 | — | — | CN | disclosed |
| CN-111518035-A | Rosuvastatin tert-butylamine salt and preparation method thereof | 安徽鼎旺医药有限公司 | 2020-08-11 | — | — | CN | disclosed |
| US-8874019-B2 | Image forming method | KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) | 2014-10-28 | — | — | US | disclosed |
| WO-2014140006-A1 | PROCESS FOR ENANTIOSELECTIVE SYNTHESIS OF 3-HYDROXY-GLUTARIC ACID MONOESTERS AND USE THEREOF | SANDOZ AG (CH) | 2014-09-18 | — | — | WO | disclosed |
| US-20130202336-A1 | IMAGE FORMING METHOD | KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) | 2013-08-08 | — | — | US | disclosed |
| EP-1472228-B1 | PROCESS FOR THE MANUFACTURE OF HMG-COA REDUCTASE INHIBITORS | NOVARTIS AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| US-20080182873-A1 | PROCESS FOR THE MANUFACTURE OF HMG-COA REDUCTASE INHIBITORS | ACEMOGLU MURAT | 2008-07-31 | — | — | US | disclosed |
| US-7371865-B2 | Process for the manufacture of HMG-CoA reductase inhibitors | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-20050070605-A1 | Process for the manufacture of hmg-coa reductase inhibitors | ACEMOGLU MURAT (CH) | 2005-03-31 | — | — | US | disclosed |
| US-20050014954-A1 | Pyrrole synthesis | CIBA SPECIALTY CHEMICALS CORP. | 2005-01-20 | — | — | US | disclosed |
| EP-1472228-A1 | PROCESS FOR THE MANUFACTURE OF HMG-COA REDUCTASE INHIBITORS | Novartis AG (CH) | 2004-11-03 | — | — | EP | disclosed |
| EP-1451179-A1 | PYRROLE SYNTHESIS | Ciba SC Holding AG (CH) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003064392-A1 | PROCESS FOR THE MANUFACTURE OF HMG-COA REDUCTASE INHIBITORS | NOVARTIS AG (CH) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003044011-A1 | PYRROLE SYNTHESIS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182873-A1 | PROCESS FOR THE MANUFACTURE OF HMG-COA REDUCTASE INHIBITORS | HMGCR, COASY, DHCR7 | MGAM 917/4885GAA 827/4885SI 514/4885 |
| US-20050014954-A1 | Pyrrole synthesis | PNPO, PPOX, DHPS | MGAM 3146/4885GAA 1947/4885SI 1656/4885 |
| US-20050070605-A1 | Process for the manufacture of hmg-coa reductase inhibitors | HMGCR, COASY, DHCR7 | MGAM 917/4885GAA 827/4885SI 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.